Fintel reports that on June 28, 2024, Truist Securities initiated coverage of Y-mAbs Therapeutics (NasdaqGS:YMAB) with a Buy recommendation.
Analyst Price Forecast Suggests 78.52% Upside
As of June 12, 2024, the average one-year price target for Y-mAbs Therapeutics is 21.57. The forecasts range from a low of 12.12 to a high of $27.30. The average price target represents an increase of 78.52% from its latest reported closing price of 12.08.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Y-mAbs Therapeutics is 110MM, an increase of 29.69%. The projected annual non-GAAP EPS is -1.13.
What is the Fund Sentiment?
There are 265 funds or institutions reporting positions in Y-mAbs Therapeutics. This is an increase of 2 owner(s) or 0.76% in the last quarter. Average portfolio weight of all funds dedicated to YMAB is 0.06%, an increase of 14.34%. Total shares owned by institutions increased in the last three months by 8.93% to 24,565K shares. 
The put/call ratio of YMAB is 0.09, indicating a bullish outlook.
What are Other Shareholders Doing?
Paradigm Biocapital Advisors holds 2,234K shares representing 5.09% ownership of the company.
Sofinnova Investments holds 2,194K shares representing 5.00% ownership of the company. No change in the last quarter.
Polar Capital Holdings holds 1,831K shares representing 4.17% ownership of the company. In its prior filing, the firm reported owning 2,057K shares , representing a decrease of 12.34%. The firm increased its portfolio allocation in YMAB by 81.72% over the last quarter.
Point72 Asset Management holds 1,527K shares representing 3.48% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 1,161K shares representing 2.65% ownership of the company. In its prior filing, the firm reported owning 1,159K shares , representing an increase of 0.14%. The firm increased its portfolio allocation in YMAB by 117.66% over the last quarter.
Y-Mabs Therapeutics Background Information
(This description is provided by the company.)
Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumors that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumors that express B7-H3.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
